Merck and Gilead Report Positive Phase 3 Trial Results for Combination HIV Pill
Merck (MRK) and Gilead Sciences (GILD) announced positive top-line results from two phase 3 trials of a combination pill containing islatravir and lenacapavir, meeting their primary endpoints. The ISLEND-1 and ISLEND-2 studies could represent an advancement in HIV treatment options.
